Moderna ‘TeenCOVE’ study: COVID-19 mRNA vaccine safe and 100% effective in adolescents

Moderna vaccine
Moderna vaccine for adolescents was generally well tolerated with a safety and tolerability profile consistent with the Phase 3 COVE study in adults

Moderna, Inc. has said that the phase 2/3 study of its COVID-19 vaccine (mRNA-1273) was found to be safe and effective in adolescents. The study known as ‘TeenCOVE’ consisted of over 3,700 participants between the ages of 12 and 17 in the US. Also Read: Explained: What is ECMO therapy and how is it useful for COVID-19 patients with lung damage

The ‘TeenCOVE’ study: The group of 3,732 adolescent who participated in the study were given 2:1 to two 100 µg doses of mRNA-1273 or placebo. Also Read: COVID-19: South African variant can break through Pfizer’s vaccine, says study conducted in Israel

  • After two doses, no cases of COVID-19 were observed in the vaccine group using the case definition from the adult Phase 3 COVE study, compared to 4 cases in the placebo group, resulting in a vaccine efficacy of 100% starting 14 days after the second dose
  • The vaccine was found to be 93% effective after one dose

Side-effects: The Moderna vaccine for adolescents was generally well tolerated with a safety and tolerability profile consistent with the Phase 3 COVE study in adults. Also Read: COVID-19 vaccine: Pfizer jab is 100% effective in trial of children between ages 12-15 years

  • No significant safety concerns have been identified to date
  • Majority of adverse reactions were mild or moderate in severity
  • Injection site pain, headache, fatigue, myalgia and chills were some of the most common adverse side-effects
  • All participants will be monitored for 12 months after their second injection to assess long-term protection and safety. Consequently

What’re they saying: Stéphane Bancel, CEO of Moderna said, “We are encouraged that mRNA-1273 was highly effective at preventing COVID-19 in adolescents. It is particularly exciting to see that the Moderna COVID-19 vaccine can prevent SARS-CoV-2 infection. We will submit these results to the U.S. FDA and regulators globally in early June and request authorization. We remain committed to doing our part to help end the COVID-19 pandemic.” Also Read: COVID-19 vaccination: Pregnant women pass immunity against coronavirus to their babies

LEAVE A REPLY

Please enter your comment!
Please enter your name here